drugset
drugset / Trial / NCT07705464

Safety Study of Intravenous MiraMSC in Older Adults With Mild to Moderate Frailty Syndrome

NCT07705464 ↗

Phase 1 Not yet recruiting 12 enrolled Miracle Biomedical Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

The purpose of this Phase I, open-label study is to evaluate the safety and tolerability of intravenous MiraMSC-FS-001 in older adults with mild to moderate frailty syndrome. MiraMSC-FS-001 is an investigational product consisting of allogeneic umbilical cord-derived mesenchymal stem cells (UCMSCs). Eligible participants will receive intravenous administration of MiraMSC-FS-001.

Timeline

Start
2026-12-01
Primary completion
2028-06-30
Completion
2028-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject MiraMSC-FS-001 Cell therapy 9e+07 cells Intravenous

Indications

No indication recorded.